Clozapine: progress in treating refractory schizophrenia.
作者信息
Hirsch S R, Puri B K
出版信息
BMJ. 1993 May 29;306(6890):1427-8. doi: 10.1136/bmj.306.6890.1427.
Abstract
摘要
相似文献
1
Clozapine: progress in treating refractory schizophrenia.氯氮平：难治性精神分裂症的治疗进展
BMJ. 1993 May 29;306(6890):1427-8. doi: 10.1136/bmj.306.6890.1427.
2
Multiple outcome assessment in a study of the cost-effectiveness of clozapine in the treatment of refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia.氯氮平治疗难治性精神分裂症成本效益研究中的多重结果评估。退伍军人事务部氯氮平治疗难治性精神分裂症合作研究小组。
Health Serv Res. 1998 Dec;33(5 Pt 1):1237-61.
3
Cost-effectiveness of clozapine treatment in therapy-refractory schizophrenia.氯氮平治疗难治性精神分裂症的成本效益
Acta Psychiatr Scand. 1995 Sep;92(3):199-201. doi: 10.1111/j.1600-0447.1995.tb09568.x.
4
Cost of monitoring clozapine.氯氮平监测成本。
Hosp Community Psychiatry. 1991 Sep;42(9):955-6. doi: 10.1176/ps.42.9.955-a.
5
Clozapine and hospitalization.氯氮平与住院治疗。
Psychiatr Serv. 1999 Jan;50(1):114-6. doi: 10.1176/ps.50.1.114b.
6
New vs. old antipsychotics: the Texas experience.新型抗精神病药物与传统抗精神病药物：德克萨斯州的经验
J Clin Psychiatry. 1999;60 Suppl 1:23-5; discussion 28-30.
7
Clozapine for refractory schizophrenia: the Illinois experience.氯氮平治疗难治性精神分裂症：伊利诺伊州的经验
J Clin Psychiatry. 1999;60 Suppl 1:18-22; discussion 28-30.
8
Pharmacoeconomic evaluation of treatments for refractory schizophrenia: clozapine-related studies.难治性精神分裂症治疗的药物经济学评价：与氯氮平相关的研究。
J Clin Psychiatry. 1999;60 Suppl 1:7-11; discussion 28-30.
9
A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia.氯氮平与氟哌啶醇治疗住院难治性精神分裂症患者的比较。退伍军人事务部氯氮平治疗难治性精神分裂症合作研究组。
N Engl J Med. 1997 Sep 18;337(12):809-15. doi: 10.1056/NEJM199709183371202.
10
Cost-benefit analysis of risperidone and clozapine in the treatment of schizophrenia in Israel.以色列使用利培酮和氯氮平治疗精神分裂症的成本效益分析。
Pharmacoeconomics. 1998 Feb;13(2):231-41. doi: 10.2165/00019053-199813020-00006.
引用本文的文献
1
Cost-benefit analysis of risperidone and clozapine in the treatment of schizophrenia in Israel.以色列使用利培酮和氯氮平治疗精神分裂症的成本效益分析。
Pharmacoeconomics. 1998 Feb;13(2):231-41. doi: 10.2165/00019053-199813020-00006.
2
Clozapine: an appraisal of its pharmacoeconomic benefits in the treatment of schizophrenia.氯氮平：对其治疗精神分裂症的药物经济学效益评估
Pharmacoeconomics. 1993 Aug;4(2):131-56. doi: 10.2165/00019053-199304020-00007.
3
Is clozapine worth its cost?
Pharmacoeconomics. 1993 Nov;4(5):311-4. doi: 10.2165/00019053-199304050-00001.
4
Community care of patients with schizophrenia: the role of the primary health care team.精神分裂症患者的社区护理：初级卫生保健团队的作用。
Br J Gen Pract. 1996 Apr;46(405):231-7.
5
Clozapine in the management of schizophrenia. All schizophrenic patients would benefit.氯氮平治疗精神分裂症。所有精神分裂症患者都会从中受益。
BMJ. 1993 Jul 17;307(6897):199-200. doi: 10.1136/bmj.307.6897.199-b.
6
Clozapine in the management of schizophrenia. Clozapine has unique pharmacological profile.氯氮平在精神分裂症治疗中的应用。氯氮平具有独特的药理学特性。
BMJ. 1993 Jul 17;307(6897):200. doi: 10.1136/bmj.307.6897.200.
7
Clozapine in the management of schizophrenia. Compliance no worse than with other neuroleptic drugs.氯氮平用于精神分裂症的治疗。其依从性并不比其他抗精神病药物差。
BMJ. 1993 Jul 17;307(6897):200. doi: 10.1136/bmj.307.6897.200-b.
8
Idiosyncratic drug-induced haematological abnormalities. Incidence, pathogenesis, management and avoidance.特异质性药物引起的血液学异常。发病率、发病机制、管理及预防
Drug Saf. 1994 Dec;11(6):445-62. doi: 10.2165/00002018-199411060-00006.
9
The short form 36 health status questionnaire: clues from the Oxford region's normative data about its usefulness in measuring health gain in population surveys.36项简易健康状况调查问卷：来自牛津地区标准数据的线索，关于其在人口调查中衡量健康收益的有用性。
J Epidemiol Community Health. 1995 Feb;49(1):102-5. doi: 10.1136/jech.49.1.102.
10
Clozapine in the management of schizophrenia. Risperidone is less toxic but equally effective.氯氮平用于精神分裂症的治疗。利培酮毒性较小但疗效相当。
BMJ. 1993 Jul 17;307(6897):200. doi: 10.1136/bmj.307.6897.200-a.
本文引用的文献
1
Assessment of costs and benefits of drug therapy for treatment-resistant schizophrenia in the United Kingdom.英国难治性精神分裂症药物治疗的成本与效益评估。
Br J Psychiatry. 1993 Jan;162:38-42. doi: 10.1192/bjp.162.1.38.
2
The effect of long-term treatment with clozapine in schizophrenia: a retrospective study in 96 patients treated with clozapine for up to 13 years.氯氮平长期治疗精神分裂症的效果：一项对96例接受氯氮平治疗长达13年患者的回顾性研究。
Acta Psychiatr Scand. 1988 May;77(5):524-9. doi: 10.1111/j.1600-0447.1988.tb05164.x.
3
Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine.氯氮平用于难治性精神分裂症。与氯丙嗪的双盲对照研究。
Arch Gen Psychiatry. 1988 Sep;45(9):789-96. doi: 10.1001/archpsyc.1988.01800330013001.
4
Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia.氯氮平作用机制的临床研究：精神分裂症的多巴胺 - 5-羟色胺假说
Psychopharmacology (Berl). 1989;99 Suppl:S18-27. doi: 10.1007/BF00442554.
5
Effects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients.六个月氯氮平治疗对慢性精神分裂症患者生活质量的影响。
Hosp Community Psychiatry. 1990 Aug;41(8):892-7. doi: 10.1176/ps.41.8.892.
6
Clozapine. A review of its pharmacological properties, and therapeutic use in schizophrenia.氯氮平：其药理特性及在精神分裂症治疗中的应用综述
Drugs. 1990 Nov;40(5):722-47. doi: 10.2165/00003495-199040050-00007.
7
Dopaminergic and serotonergic effects of clozapine. Implications for a unique clinical profile.氯氮平的多巴胺能和5-羟色胺能效应。对独特临床特征的影响。
Arzneimittelforschung. 1992 Feb;42(2A):268-72.
8
Clinical and biologic response to clozapine in patients with schizophrenia. Crossover comparison with fluphenazine.精神分裂症患者对氯氮平的临床及生物学反应。与氟奋乃静的交叉对照比较。
Arch Gen Psychiatry. 1992 May;49(5):345-53. doi: 10.1001/archpsyc.1992.01820050009001.
Zotero 插件